French biotech and Pfiz­er find pos­i­tives in da­ta for Ly­me dis­ease vac­cine can­di­date; Al­tim­mune's obe­si­ty drug shows promise in PhI tri­al

French biotech Val­ne­va and part­ner Pfiz­er con­tin­ued to re­veal pos­i­tive re­sults from its Phase II tri­al for its Ly­me dis­ease vac­cine can­di­date.

The Phase II study, which en­rolled 246 healthy adults be­tween 18-65 in the US, met its pri­ma­ry end­point last Oc­to­ber, demon­strat­ing that the can­di­date, known as VLA15, was im­muno­genic across all dose groups test­ed and elicit­ed high an­ti­body re­spons­es one month af­ter the pri­ma­ry vac­ci­na­tion se­ries. Con­tin­ued eval­u­a­tion at Month 18 showed that an­ti­body titers de­clined across all groups, but re­mained above base­line, con­firm­ing the need for a boost­er.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.